Abstract | OBJECTIVES: The aim of this integrated analysis is to evaluate the long-term safety and tolerability of ixekizumab in adults with psoriasis, PsA and axial SpA. METHODS: Integrated safety data from 21 clinical trials are presented by indication in patients who received at least one dose of ixekizumab. Adverse events (AEs) and treatment-emergent adverse events (TEAEs) adjusted incidence rates (IRs) per 100 patient-years (PY) up to 5 years' exposure are reported. RESULTS: CONCLUSION: This long-term analysis on the safety of ixekizumab was consistent with previously published reports and did not show any new safety signals. The safety profile and tolerability reported in this integrated analysis remained consistent with the known safety profile for ixekizumab.
|
Authors | Mark C Genovese, Eduardo Mysler, Tetsuya Tomita, Kim A Papp, Carlo Salvarani, Sergio Schwartzman, Gaia Gallo, Himanshu Patel, Jeffrey R Lisse, Andris Kronbergs, Soyi Liu Leage, David H Adams, Wen Xu, Helena Marzo-Ortega, Mark G Lebwohl |
Journal | Rheumatology (Oxford, England)
(Rheumatology (Oxford))
Vol. 59
Issue 12
Pg. 3834-3844
(12 01 2020)
ISSN: 1462-0332 [Electronic] England |
PMID | 32449924
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Dermatologic Agents
- ixekizumab
|
Topics |
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects)
- Arthritis, Psoriatic
(drug therapy)
- Dermatologic Agents
(administration & dosage, adverse effects)
- Drug Hypersensitivity
- Humans
- Infections
(chemically induced)
- Injection Site Reaction
- Randomized Controlled Trials as Topic
- Spondylarthritis
(drug therapy)
|